NVCR News and Press, NovoCure Limited From 04/07/22

One group stands out as an interesting and potentially dramatically undervalued area of the market in the wake of the pandemic and its historical footprint: Medical device stocks. The healthcare system has been forever changed by the pandemic, which accelerated several core healthcare industr...

Biotech stocks, in general, again performed dismally in the first quarter of 2022. However, there are some signs of improvement. The lower valuations could present a great buying opportunity once the inevitable strong rebound materializes. We asked three Motley Fool contributors which b...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2022 on Thursday, April 28, 2022, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the thr...

Novocure (NASDAQ: NVCR) could either be a big win or a deep dip for investors. In this clip from "3 Minute Stocks Updates" on Motley Fool Live , recorded on March 2 , Motley Fool contributor Brian Feroldi discusses the reasons why this medical device stock could go either wa...

Patients in phase 2 pilot trial 2-THE-TOP had median progression-free survival of 12.1 months compared with 7.9 months for matched-control patients from EF-14 Novocure (NASDAQ: NVCR) today announced that Dr. David Tran, Chief of the Division of Neuro-Oncology at the McKnight...

An independent data monitoring has recommended that a phase 3 trial of Novocure's (NASDAQ:NVCR) Tumor Treating Fields (TTFs) for ovarian cancer should continue following an interim analysis. The analysis showed that an increase in sample size is not necessary and the committee recommended tha...

Pre-specified interim analysis concluded that the INNOVATE-3 study should proceed to final analysis as planned Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 pivotal INNOVATE-3 study evaluating the safety and efficacy ...

One positive spin we can put on the “great growth stock bear market of 2022” – which, let’s face it, is what we are dealing with so far this year – is the value being created for future portfolio returns. We have seen indiscriminate selling in many high-grow...

March is the month when most of us like to see some green. But in addition to the greenery in the great outdoors (and on St. Patrick's Day), investors would also like to see some green in their portfolios. Three Motley Fool contributors took at look at some biotech stocks that could mak...

NovoCure's revenue growth has slowed down in recent quarters. COVID-19 is having an impact, but Optune in GBM is also in a more mature stage with 35% market penetration in existing markets. Longer term, there are significant growth opportunities in the GBM market, driven by device...